Equity Profile
Pre-Earnings Brief
Novartis AG (NVS) is a global healthcare company that focuses on developing and manufacturing innovative pharmaceuticals. With a market cap of $274 billion, it plays a crucial role in the healthcare sector, especially in areas like oncology, cardiology, and immunology.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and is closely watched by investors.
Revenue Growth
Revenue growth reflects the company's ability to expand its market share and introduce new products.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
75%
Avg EPS Surprise
+3.66%
Avg Stock Reaction
-1.57%
In Q1 2026, Novartis reported an EPS of $1.99, which was below the expected $2.11, resulting in a 5.6% surprise. The stock saw a modest increase of 0.91% the following day.
Management Promises & Guidance
Overall expectations for Novartis are mixed as the company faces challenges in meeting earnings estimates while also having a strong drug pipeline.
Bull Case
If Novartis can successfully launch new drugs and show strong revenue growth, it could lead to increased investor confidence and a higher stock price.
Bear Case
Conversely, if the company continues to miss earnings estimates and fails to provide clear guidance on future growth, it may lead to a decline in stock value.
Earnings Per Share (EPS)
N/AEPS is a key indicator of the company's profitability and is closely watched by investors.
Revenue Growth
N/ARevenue growth reflects the company's ability to expand its market share and introduce new products.
Pipeline Developments
N/AUpdates on the drug pipeline can significantly impact future revenue potential and investor confidence.
Expectations
The print will turn on these two things.
Q1
What is the expected revenue growth from new product launches this quarter?
This will indicate how well Novartis is executing its growth strategy and could influence investor sentiment.
Q2
How is the company addressing recent challenges in its drug pipeline?
Management's response will be critical in assessing the future potential of Novartis' offerings and overall market position.
Edge
Why consensus could be wrong
The Street may be underestimating Novartis' potential for revenue growth from its upcoming drug launches, which could significantly outperform current expectations.
Supporting Evidence
Options are pricing a 4.44% move, suggesting higher volatility than historical averages.
The company's strong pipeline could lead to unexpected positive surprises in revenue.
Key Risk
If new product revenues exceed initial estimates, it could challenge the current bearish sentiment.
Edge
Pre-commit to what would confirm each case.
The market is weighing Novartis' ability to innovate against its recent struggles with earnings surprises.
Bull Confirmed If
Successful launch of at least two new drugs with projected revenue growth exceeding 10% YoY.
Bear Confirmed If
Failure to meet EPS expectations again, particularly if the miss exceeds 5%.
Pre-Earnings Positioning
Implied Move
±4.44%
Historical Avg
±2.5%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±6.0% while NVS has averaged ±2.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.2%
30d HV
21.1%
Edge
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
n=30Fade rate: 12 of 27 (44%)
This setup has occurred 30 times across Health Care in the last 2 years. 12 of 27 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 6.0%, with a raw directional average of +3.0% (modestly positive historical bias).
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Novartis beats expectations, history suggests the stock could rise by around 1.5% on the first day, confirming a positive outlook.
In-Line / Cautious
If results are in line but cautious, the stock may see little movement as investors reassess future growth potential.
Miss
A miss could lead to a decline of about 1.76% based on historical patterns, raising concerns about the company's growth trajectory.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Domino's Pizza, Inc.